GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Insider Ownership

KYTX (Kyverna Therapeutics) Insider Ownership : 0.41 % (As of Dec. 11, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Kyverna Therapeutics's insider ownership is 0.41%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Kyverna Therapeutics's Institutional Ownership is 68.47%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Kyverna Therapeutics's Float Percentage Of Total Shares Outstanding is 76.85%.


Kyverna Therapeutics Insider Ownership Historical Data

The historical data trend for Kyverna Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Insider Ownership Chart

Kyverna Therapeutics Historical Data

The historical data trend for Kyverna Therapeutics can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Insider Ownership 0.37 0.35 0.35 0.39 0.41 0.41 0.41 0.41 0.41 0.41

Kyverna Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Kyverna Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.